Jump to content

MaryO

~Chief Cushie~
  • Posts

    8,032
  • Joined

  • Last visited

  • Days Won

    536

Everything posted by MaryO

  1. http://story.news.yahoo.com/news?tm....ow_dc_1 Argentina Cow Clone Step Toward Cheaper Growth Drug Fri Aug 16, 5:20 PM ET By Matias A. Loewy BUENOS AIRES (Reuters Health) - The Spanish-speaking world now has its first cloned calf: "Pampa," a female born in Argentina last week. The 37-kilogram Jersey calf was delivered by C-section after 278 days gestation and a global investment of $2 million. Scientists who conducted the project consider Pampa's birth a step in the development of cloned and genetically modified cows capable of producing "more affordable" human growth hormone (hGH) and other expensive medicines, they said this week at a press conference. This requires inserting the human gene responsible for producing the hormone into an embryo, theoretically making it possible for the mature animal to produce hGH in its milk. The birth of four calves containing the gene is expected in September, Dr. Carlos Melo, research and development manager at Bio Sidus, the company directing the research, told Reuters Health. But it will be some time before they can produce the hormone, Melo added. "Within 4 years we may have a (decent number) of cows producing daily several grams of hGH in their milk," Melo told Reuters Health. HGH from milk might be as much as 90% cheaper than the hGH now available, Melo told Reuters Health. In Argentina alone, some 1,000 children with dwarfism take the hormone daily to foster normal growth. Pampa's birth places Argentina among the nine countries in the world capable of cloning livestock. The cloning technique involves removing the nucleus from a bovine egg cell and replacing it with the nucleus of a fetal cell-skin fibroblast, previously obtained from the animal to be copied. In order to get pharmaceutical products from the milk, scientists must insert the human gene of interest into the embryo before implanting it into a surrogate mother cow. An adult Jersey cow produces around 10 liters of milk a day, at least 200 days in the year. Bio Sidus expects that every single cloned cow would eventually produce 2 kilograms of raw hGH each year. Once hGH is collected in the milk, scientists will have to purify and formulate it as medicinal product. "The whole process might imply losing around 50% to 80% of the original amount of the protein," Melo said. The product is not expected to reach the market before 2008. Bio Sidus is already producing recombinant hGH by conventional bacterial fermentation, but cloning technology might allow the company to dramatically increase its current level of production. In the future, Bio Sidus also plans to apply the technology to produce human tissue plasminogen activator (tPA), a potent clot-dissolving drug used to treat heart attack and stroke. Bio Sidus SA is the biotech branch of the pharmaceutical group Sidus, founded in Argentina in 1938. The company manufactures five recombinant proteins, such as erythropoietin and filgrastim, and exports around 70% of its production to almost 40 countries.
  2. http://www.washingtonpost.com/wp-dyn/artic...-2002Aug13.html Hormone Replacement Gets New Scrutiny Finding of Increased Risks Prompts Federal Effort By Marc Kaufman Washington Post Staff Writer Wednesday, August 14, 2002; Page A01 Federal officials announced yesterday that they have begun a major reassessment of the risks and benefits of all combination hormone products containing estrogen used by post-menopausal women, one month after a large government study found potentially serious side effects from hormone replacement therapy. The federal effort could change how popular drugs such as Prempro are advertised, prescribed and used, with new recommendations about who should take them, at what dosages and for how long. The initiative, which will include several public forums this fall sponsored by the National Institutes of Health, the Food and Drug Administration and the Agency for Healthcare Research and Quality, will also try to guide future research on the suddenly more complex and controversial subject. The move marks the first significant action by the federal government in response to the latest findings about hormone therapy. It is designed to address the widespread confusion that has caused anxious women to inundate doctors with questions about whether they should continue taking the powerful hormones. "Somebody needed to take a leadership role, because there is chaos in the medical societies," said Wulf H. Utian, executive director of the North American Menopause Society, who has been invited to participate in the meetings. "It's time to clear the air and address the issues." The brief announcement of the initiative came as the FDA separately pushed for immediate changes in the label and the package insert for the hormone combination sold as Prempro to reflect the risks confirmed by the Women's Health Initiative (WHI). Part of that federally funded study was stopped three years early because of small but statistically significant increases in heart disease, breast cancer, stroke and blood clots among women taking Prempro, a combined estrogen-progestin drug. While the study used only Prempro, agency officials said they have new questions about other estrogen-progestin products on the market, as well. In response to the immediate FDA concerns, officials at Wyeth Pharmaceuticals, maker of Prempro, said the company expects to submit new safety precaution information as early as this week that will take into account the WHI findings. The WHI study was testing the widely held hypothesis that hormone therapy reduced the risk for heart disease in particular and, so, was especially surprising. "The FDA says it is our responsibility to get new information out there, and we agree," said Bruce Burlington, Wyeth's vice president for regulatory compliance. He said that many of the WHI findings on increased risks to women were already known and incorporated into the Prempro label but that "the risks were better quantified in WHI." These initial steps can be taken without formal FDA approval. But officials said that they are aggressively reviewing hormone replacement therapy generally -- now used by 14 million menopausal and post-menopausal American women -- and that more wide-ranging changes can be expected. As part of the effort, federal officials want to explore whether hormone therapies and their producers have encouraged women to believe menopause is a condition to be treated, rather than an inevitable and natural set of changes to be managed. The hormone therapy issue is being actively debated within medical societies, too, with the American College of Obstetricians and Gynecologists, the North American Menopause Society and others forming task forces on hormone replacement in response to the WHI findings. Reflecting the FDA's discomfort with the way that hormone treatments have been widely presented as an antidote to menopause, the agency has told Wyeth to remove all references to "hormone replacement therapy" from its Prempro label. The "replacement" model, officials said, has never been accepted by the agency, which approved Prempro for specific symptoms of menopause and to prevent osteoporosis, a reduction in bone mass. "The impact of the WHI findings [is] very far-reaching, and that fact is not lost on the FDA," said Florence Houn, a director at the FDA's Center for Drug Evaluation and Research. "As a public health agency, we need to step to the plate and reassess the risk-benefit conditions for labeling and risk management for patients." Estrogen products have been used for decades and have helped millions of women handle the sometimes-severe symptoms of menopause, including hot flashes, night sweats, sexual discomfort and the increased risk of bone fractures. For years, studies on heart disease, Alzheimer's, colon cancer and bone fractures also showed potential benefits to women taking hormone replacement long-term, and those findings were widely embraced by doctors and advertised by the drugmakers. The earlier positive findings on estrogen and heart disease, for instance, were considered strong enough by the American Heart Association to be included in its literature for women as recently as 1997. But studies in the past several years began to raise doubts about the benefits and risks from long-term hormone therapy, and the large WHI study concluded that hormone therapy actually increased the risk of heart disease. That finding has required a quick pivot by medical authorities, individual doctors and, now, federal officials. Further complicating the picture, the WHI study found that hormone therapy did help protect women against colon cancer and hip fractures. In addition, another arm of the WHI study did not find cardiovascular and cancer dangers with estrogen treatment alone (as opposed to the estrogen-progestin combination) when it was used by women who have had hysterectomies. That part of the study was allowed to continue. The FDA expects to hold an expert advisory meeting this fall or winter to make recommendations about how hormone therapies should be used. Among the issues to be addressed are whether hormone treatment should be limited to several years, whether all hormone combinations containing estrogen carry the same risks, and whether estrogen-combination products require the kind of more prominent black box warnings that are used for drugs with potentially fatal side effects. Although the WHI study did not find an increase in deaths from breast cancer, heart disease or stroke before it was stopped, the study did conclude that Prempro was associated with a greater risk of those diseases. "Ultimately, the label that does get full FDA approval may well look quite different from what the company feels is needed for immediate strengthening," Houn said. The FDA-approved label for a drug is key to how it is advertised, prescribed and used by patients. While doctors can write prescriptions off-label, companies can advertise to consumers and doctors only the uses approved by the FDA, and they must convey the side effects deemed serious by the agency. Wyeth officials said that since the WHI study was discontinued, they have stopped direct-to-consumer advertising about hormone replacement but increased visits to doctors to explain the results. ? 2002 The Washington Post Company
  3. http://www.acurian.com/patient....lcthtml Summary: Androgen Replacement Therapy in Women with Hypopituitarism This is a 12-month study investigating the effects of a natural hormone on bone formation, body composition, quality of life, cognitive function and libido. The study involves blood sampling, questionnaires and tests to determine bone density and the amount of fat and muscle in the body. Subjects will receive up to $600 for 6 outpatient visits after a screening visit determines eligibility. Patient Inclusion/Exclusion Criteria: Women ages 18-50 with adrenal insufficiency and/or estrogen deficiency from pituitary problems. Contact: Karen Miller MD Massachusetts General Hospital Fruit Street Neuroendocrine Boston, MA 02115 Telephone: 617-724-7388 Email: kkmiller@partners.org ~~~~~~~~~~~~~~~~~~~~~~ Center Overview The Massachusetts General Hospital has a long, rich, and diverse tradition of excellence in clinical research that continues to expand today. The extensive resources for training clinical investigators and performing top quality translational investigation include: An integrated full service primary, secondary, and tertiary care hospital network with access to large numbers of both local patients with common diseases and national and international patients referred for evaluation of rare disorders, over 600,000 square feet of research space, and a diverse population of thousands of basic and clinical scientists studying topics ranging from very basic molecular biology to direct patient management. The MGH Clinical Research Program (CRP) was established to improve the environment for clinical investigation at the MGH through academic enrichment programs and direct support services, creating a culture in which all forms of clinical research can flourish. Its mandate is to: Enhance bench to bedside research Train clinical investigators Increase clinical trial activity Support outcomes research and disease management Coordinate the MGH's efforts with those of Partners HealthCare System and Harvard Medical School The CRP serves as the institutional infrastructure that encourages and supports its physician scientists by serving as an interface between clinical investigators and sponsors of clinical trials and outcomes research. We work to: Explore preferred relationships with pharmaceutical and biotech companies Link industry to physicians for consulting, advisory board seats, and trials Provide outcomes and disease management expertise Support the administration of clinical trials Negotiate master clinical trial agreements The CRP provides a high level of clinical trial services to help investigators compete and meet the demands on industrial sponsors. Services to PIs include: Assistance with the IRB application Preparation and negotiation of budgets Contact facilitation Assistance in patient recruitment Data management support Assistance with strategy and proposal development for corporate-sponsored and investigator-initiated clinical trials Assistance with the development of large multi-center grant applications In addition to its role as a facilitator, the CRP has developed and sponsored a series of educational courses and seminars for current and future investigators and study coordinators. These activities not only improve the quality of the investigators and study coordinators but also raise awareness within the institution about clinical research. Mentoring is available to young researchers by fostering collaborations with established investigators. New investigators are offered career advice and assistance in developing and conducting research studies. Since communication plays a critical role within the research community, the CRP has developed an interrelated set of communication and clinical research tools: CRnet an on-line information source about clinical research at MGH; web-based query tools and patient data registries to characterize patient populations and assess clinical trial feasibility; software and databases for investigator-initiated patient data registries and disease management studies; and direct technical support for the clinical investigative community. The Clinical Research Program provides the infrastructure necessary to support clinical research on an institution-wide basis. By fostering academic collaboration, effecting communication with industrial sponsors and promoting a focused and streamlined administrative process, the CRP is building a responsive culture conducive to clinical investigation.
  4. Wow, thanks for this, Kristy - I remember when Della's daughter died, we'd wondered what kind of pit tumor she'd had. I guess it wasn't Cushing's, but certainly scary enough! I hope she continues to speak out about this. We need all the "talkers" we can get!
  5. Anyone interested in any of these? ?You can see them, un-logo'd here They're offering for "Back to School": Backpack (black) Metro Bag (black) Unistrap Bag (black) Briefcase (black) Yellow Messenger Bag Ash Grey Hoodie Black Cotton Cap Retro Lunch Box Coming later this month! The black cotton caps and black bags are customized using a 4" x 2" patch with an embroidered edge. Let me know, please, if there's any interest,,,
  6. After I got rolling, it wasn't too hard. I should have planned ahead myself - I got my first t-shirt, totebag last week, then I went back and got some more stuff...then I ordered the travel mug with my name on it for Convention use. I shudda waited, too, but I didn't want to miss the hat sale, either.
  7. A variety of coffee mugs, including personalized and travel, are now available in the Cushing's Store ?There are currently 54 different products to choose from, all of which support these websites and CUSH. I've made some with slogans to put on mugs for endos or other supportive people, but I'm open to other ideas if anyone has any thoughts...
  8. The perfect place! Thanks, Sarah
  9. MaryO

    T-shirts

    I'm going nuts here. I just ordered another Tshirt for me (Cushing's Survivor), a Support Staff for Tom, a beach hat and... well, I really love my coffee, so I made myself a personalized travel mug. If anyone else would like something similar, just let me know. If you're interested, you can see what I did here
  10. The $3.00 sale is only until the 28th. I don't know if the hats will go back to normal price then, of if they'll disappear until next summer.
  11. MaryO

    T-shirts

    Also done in all 9 shirt styles are Cushing's Support Staff, and Cushing's Survivors. All 36 shirt styles, the hats, mugs, visors and totebag are on one big page click here for the Cushing's Store The Golf and Baseball shirts don't have any design on the back. If anyone wants them on, please let me know. Also, if you want a special order, with your name printed on it, let me know. As always, each shirt provides $1.00 to the running of this site and $1.00 to CUSH.
  12. MaryO

    T-shirts

    The Cushie Crusader shirts (9 styles) are done now. View everything here: All Cushie products to date
  13. The first of the Hats and Visors are ready. And, they're on sale! ?$3.00 off each. ?I think that means they're going away soon, since the summer's almost over. View them in http://www.cafepress.com/cp....support
  14. http://health.yahoo.com/search/healthnews?lb=s&p=id%3A25877 Recent Findings from the Women's Health Initiative Trial Regarding Risks and Benefits of Estrogen-Progestin (Combined Hormone Replacement Therapy) in Healthy Postmenopausal Women July 26, 2002, Acurian Source: Brigham and Women's Hospital On July 10, 2002, the results of a large study looking at the effects of hormone replacement therapy (a combination estrogen-progestin pill, also known as Prempro) on healthy postmenopausal women was published. This study, the Women's Health Initiative, is a federally funded, national study. Brigham and Women's Hospital is one of the 16 Vanguard Centers in this study of about 16,000 healthy postmenopausal women, half of whom took a combination pill of estrogen and progestin and the other half took a placebo, or "dummy" pill. 1. Why is this study in the news at this time? The study was stopped early (after average follow-up time of 5.2 years) because the risk of invasive breast cancer was found to be slightly increased in the women who were taking the estrogen-progestin pills. In addition, the overall risks of the hormones were found to be greater than the benefits at this point. 2. What were the key findings of the study? There were slight increases in the rates of heart attacks, breast cancer, blood clots in the lungs, and stroke. The total number of women who had these outcomes was very small, but more women in the hormone group had these events than women in the placebo group. Overall, it was calculated that if 1000 women took the medication for 10 years, there would be 7 more heart attacks, 8 more cases of breast cancer, 8 more strokes, and 8 more blood clots in the women who took the hormones compared to those who did not. 3. If I am taking hormone replacement therapy, should I stop? This depends on why you are taking the medication and for how long. If you have been taking the medication for over five years, you should talk to your doctor about stopping. If you were started on this medication for hot flashes that were preventing you from performing your daily activities, and you have been taking the medication for less than 5 years, you should discuss staying on the medication with your doctor. This would be a good time to review the risks of the medication once again with your doctor. 4. What if I am taking estrogen only? There is a separate study being conducted by the Women's Health Initiative that is looking at the effects of taking estrogen only (no progestin, such as Provera). This study has NOT been stopped, since so far, there is no evidence of increased risk of breast cancer. You should only be on estrogen alone if you do not have a uterus (in other words, if you have had a hysterectomy). If you are taking estrogen alone and have a uterus, please talk to your doctor about this, since there is an increased risk of uterine cancer in women who have a uterus taking estrogen without a progestin. 5. What about transdermal estrogens (skin patches), or other forms of hormone replacement therapy? The Women's Health Initiative specifically studied the effects of the combination premarin (conjugated equine estrogens) and provera (medroxyprogesterone acetate) since this is the preparation that was shown to be beneficial in previous observational trials. Although these findings do not directly apply to other types of hormone replacement therapy, such as skin patches, synthetic estrogens, or other forms of progestin, there is very little evidence that these other forms of estrogen provide any benefit and they are not recommended at this time. 6. Are there any benefits to being on HRT? The study did find small decreases in the risk of bone fractures and colon cancer, but these benefits are smaller than the risks listed above. The National Cancer Institute has stated specifically in response to this study, however, that HRT should not be used for the purpose of preventing colon cancer. 7. Is there a greater risk of death for people on HRT? No, this study did not show an increase in death rates in the women taking the medication. 8. If I choose to stop the medication, can I quit "cold turkey"? Yes. If you have a return of your menopausal symptoms after quitting, you can go back on the medication and discuss with your doctor a slower tapering of the medication. 9. Do I need to quit taking the medication immediately? No, this is not an emergency. The absolute risk of being on this medication is still quite low, but enough to raise concerns about staying on the medication long-term. You may wait until your annual appointment with your doctor to discuss more fully. 10. What else could I use for my menopausal symptoms? Other treatments are available for the treatment of hot flashes, including medications called SSRIs, which are also used for depression or (MaryO Note: They didn't say what went after the "or"). For symptoms of vaginal dryness, vaginal estrogen preparations may be used, which are absorbed only minimally into the bloodstream. Some patients have used soy supplements or increased their dietary soy intake and have found this to be effective in reducing hot flashes, although there are no good studies proving that soy products are really beneficial. 11. What if I was taking HRT to reduce my risk of osteoporosis or heart disease? There are several other excellent treatment options for osteoporosis which you should discuss with your doctor. At the present time, there is no evidence that combination hormone replacement therapy prevents heart disease. However, there are other medications that have been shown to prevent heart disease (such as aspirin, cholesterol lowering drugs, and others) and you should discuss whether any of these medications would be of benefit to you. Finally, many lifestyle changes, such as getting regular exercise, eating a healthy diet, maintaining a healthy body weight, quitting smoking, and limiting your alcohol intake have been shown to be very effective in preventing heart disease.
  15. http://hsc.virginia.edu/medcntr....ch.html Pituitary Research The following pituitary research is underway at the University of Virginia Health System. Neural net analysis in Cushing's disease (Reitmeyer) Visual disturbances in Cushing's disease - corneal edema, lens alterations, glaucoma (Newman) IGF-1 pre- and postop Outcome assessments for Gamma Knife radiosurgery (Vance) Recovery from pit insufficiency after surgery Metabolic (functional) imaging of pit tumors treated by medical Rx and Gamma Knife SPECT studies of pit adenomas (octreotide, MIBG) Intraoperative measurement of ACTH, GH, PRL (Pajewski) Genomic instability in recurrent adenomas (Clayton) Genomic comparisons by age within tumor groups (e.g. PRL, GH, NFA's Cushing's) Genomic comparisons by tumor subtype for acromegaly Genomic characterization of aggressive (malignant) adenomas Probe nl pit for nestin (precursor marker) & correlate with tumors Characterization of DA unresponsive prolactinomas (receptors, genome) Hypothalamic hormones as ligands for treatment ER mutations in pit adenomas (Shupnik) X- inactivation clonality studies in nl pit, 1? tumors and 2? tumors - sheep pits IGF-1 and IGF-1R in invasive adenomas (consider also EGPR, VEGF) (Lopes) CMR or CBF studies in Cushing's (correlation with cerebral atrophy) TRH Stimulated GN adenoma suspects tested for ? su, FSH, LH POMC to follow silent ACTH tumors - in situ hybridization for D2 receptors -? monoclonal origin of tumor Time course of cortisol decrease in operated Cushing's disease patients (Simmons-Thorner) Outcome assessment of pts. with craniopharyngioma (Rogol) CDNA probes for MEN-1 genes in sporadic pituitary adenomas Pituitary tumor cell culture and chemosensitivity testing (Kornblith) Molecular defects in GH adenomas (Cutler & Selman) Maintenance and cataloging of pituitary tumor tissue and blood bank (Wagner-Lopes) Pituitary tumor data base project (Thorner-Boyd) CDNA libraries for aggressive, recurrent and unusual adenomas Cerebral atrophy on MRI in Cushing's patients and control
  16. MaryO

    T-shirts

    Ok... Cushie Crusader and Cushing's Supporter coming up on all 9 of the shirts and Cushing's Expert, Cushie Crusader and Cushing's Supporter each coming up on the 3 types of hats we have...visor, beach hat and baseball cap. 27 new products - AARRGGHH.......................... Should keep me out of trouble
  17. Abbott Laboratories' SYNTHROID® (Levothyroxine Sodium Tablets, USP) Confirmed Safe and Effective Through FDA approval FDA Approves 47-Year Old Drug For Use in Managing Thyroid Disease ABBOTT PARK, Ill., July 24 /PRNewswire/ -- Abbott Laboratories announced today it received U.S. Food and Drug Administration (FDA) approval of its synthetic thyroid hormone replacement therapy, SYNTHROID® (levothyroxine sodium tablets, USP), for thyroid disease management, as replacement or supplemental therapy for hypothyroidism (underactive thyroid) and pituitary thyroid stimulating hormone suppression. Millions of patients and their physicians have relied on SYNTHROID for decades to maintain their thyroid health. Formal approval by FDA of SYNTHROID validates its safety and efficacy. With FDA approval, Abbott is now free to meet full market demand. "Today's FDA approval is good news for the millions of Americans who rely on SYNTHROID every day to control their thyroid disease," said Jeffrey Leiden, M.D., Ph.D., Abbott's chief scientific officer and president, Global Pharmaceuticals. "This approval confirms that SYNTHROID is safe and effective. SYNTHROID is the same drug, and patients should continue to take their medication as they always have." SYNTHROID is the number one prescribed treatment for hypothyroidism and the second most-prescribed medication overall in the United States. It is the most-studied levothyroxine sodium product, the subject of hundreds of clinical studies and featured in articles in prominent peer-reviewed medical journals. Major medical societies and patient-focused organizations -- including the American Association of Clinical Endocrinologists, the Endocrine Society, the American Thyroid Association, the Thyroid Foundation of America, and the Thyroid Cancer Survivors' Association -- publicly supported the continued use of SYNTHROID for the millions of patients on the medication during the FDA's review. Their support reinforces the importance of this product to patients. "Today's FDA approval ensures that patients will continue to have access to this vital medication, which has been relied upon by physicians and patients for almost 50 years," said Paul Ladenson, M.D., director of the Division of Endocrinology and Metabolism at Johns Hopkins Medical Institutions. "The approval of SYNTHROID is an important milestone in Abbott's commitment to patients and thyroid disease," said Dr. Leiden. "Abbott continues to conduct research to bring new and better treatment options to market." Levothyroxine Products Are Not Therapeutically Equivalent to SYNTHROID The FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), does not list any levothyroxine sodium products as therapeutically interchangeable with SYNTHROID. Switching SYNTHROID patients to another brand of thyroid medication would require testing and retitration, if necessary. AACE guidelines recommend that patients who are switched must be retested and retitrated, which would be costly, time consuming, and potentially disruptive to patients. SYNTHROID Approved as Safe and Effective Synthroid is indicated as replacement or supplemental therapy for primary, secondary, tertiary and subclinical hypothyroidism. Synthroid is not indicated for transient hypothyroidism during recovery of subacute thyroiditis. Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. Levothyroxine is contraindicated in patients with untreated subclinical or overt thyrotoxicosis, acute myocardial infarction, uncorrected adrenal insufficiency, or with hypersensitivity to any of the inactive tablet ingredients. Levothyroxine should not be used in the treatment of male or female infertility unless this condition is associated with hypothyroidism. Use with caution in patients with underlying cardiovascular disease. Adverse reactions associated with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage. If a patient experiences any unusual symptoms, a healthcare provider should be contacted. The thyroid, a butterfly-shaped gland located in the neck just below the Adam's apple and above the collarbone, produces hormones that influence essentially every organ, tissue and cell in the body. Thyroid disease affects an estimated 13 million Americans, but approximately half do not know they have the condition. Women are five times more likely than men to develop hypothyroidism. Further information, including SYNTHROID full prescribing information, is available at www.SYNTHROID.com or by calling 1 (800) 255-5162. Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com . 07/24/2002 17:38 EDT
  18. MaryO

    T-shirts

    My shirt and totebag came today. I thought I'd ordered more shirts, so now I have to go back and get some more. I ordered mine before the change in the back, so I don't have the tollfree number there. I was thinking about a couple other designs today. Cushie Crusader on the front and maybe Cushing's Supporter for the others in our lives. Thoughts?
  19. http://www.acurian.com/patient....lcthtml Trial Information Summary: Long-Acting Growth Hormone Study Protocol The purpose of this Phase I research study is to determine if an investigational, long-acting growth hormone preparation is safe for human use, to measure its levels in blood, and to determine the most effective dose to give to patients who produce less growth hormone than normal. If you qualify for this study, you would receive either a single dose of the long-acting growth hormone or two doses 7 or 14 days apart. If you receive a single dose, you would spend 24 hours immediately thereafter as an inpatient in the Clinical Research Center at the University of Pennsylvania and then make 12 or 13 outpatient visits there during the next 27 days. If you receive two doses, you would spend 24 hours as an inpatient at the Clinical Research Center after each of the two doses and then make 17 or 18 outpatient visits there during the next 34 days. Inclusion Criteria: Ages 18 - 65 years Pituitary or hypothalamic disease causing deficiencies of thyroid, adrenal, and gonadal hormones Replacement of thyroid, adrenal, and gonadal hormones Exclusion Criteria: Acromegaly Active significant acute or chronic disease Diabetes mellitus, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus or carpal tunnel syndrome Cancer within the last 5 years except for adequately treated skin cancer Allergy to yeast products Pituitary surgery within the last 3 months Pregnancy or nursing Contact: Louise Loh, RN, Research Coordinator University of Pennsylvania Health System Division of Endocrinology First Floor Maloney Building 36th and Spruce Streets Philadelphia, PA 19104 Telephone: 215-898-5664 Fax: 215-662-4500 Email: lohl@mail.med.upenn.edu
  20. http://www.acurian.com/patient....lcthtml Summary: Hypopituitary Control and Complications Study Dr. Stanley Korenman of UCLA's Division of Endocrinology is conducting a study to look at the effects of the long-term use of Growth Hormone Therapy (Humatrope, an FDA approved medication). The study involves measurements of blood levels of hormones, bone density and body fat every 6 months for 5 years (a total of 11 visits). Study Criteria: Be over 18 years of age Have known pituitary disease, either as a child or as a result of pituitary tumors Be taking hormone replacement Have health insurance Be interested in Growth Hormone Therapy Contact: Care Felix, Clinical Research Coordinator UCLA Medical Center Office of Clinical Trials 10900 Wilshire Blvd, Suite 170 Los Angeles, CA 90024 Telephone: 310-794-8900 Fax: 310-794-8902 Email: cfelix@mednet.ucla.edu
  21. MaryO

    T-shirts

    Ok...toll-free number added, but I don't know how legible it is
  22. MaryO

    T-shirts

    I was going to, and I might add it later, but I'm having trouble geting volunteers to answer it. You know I can't do that all the time...or often
  23. MaryO

    T-shirts

    Here's the front and back of most of them. http://www.cafeshops.com/cp....es#zoom Some have the front centered, and some are over to the side. Some, like the golf shirt and the baseball shirt are front only. The baseball one has black, red or blue sleeves.
  24. MaryO

    T-shirts

    T-shirts are now here! See them at http://www.cafeshops.com/cp/store.aspx?s=cushings Size Chart Jr. Baby Doll T-shirts Small (0-2) Medium (2-6) Large (6-12) T-shirt, Long Sleeve, Sweatshirt, Tank Tops Small (34-36) Medium (38-40) Large (42-44) X-large (46-48) 2X-large (50-52) 3X-large (54-56) 4X-large (58-60) Each provides $1 profit to CUSH and $1 for the running of these boards and websites. Available are: White T-Shirt, $15.99 each, Perfect for wearing to the Convention! Product Number: 1853115 In Stock: Will ship in 2-3 business days. Product Information: The most comfortable t-shirt ever! Our 100% cotton, Hanes Beefy-T is preshrunk, durable and guaranteed. 6.1 oz. fabric - luxuriously soft 100% cotton ring-spun yarn Double-needle coverseamed neck Taped shoulder-to-shoulder Double needle sleeve and bottom hems Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash. Jr. Baby Doll T-Shirt, $16.99 each Product Information: Our super soft 100% combed cotton, ribbed baby doll T-shirt from American Apparel will keep you in style. Special details include 1/2" binding on neck and sleeve with 1" bottom hem. Size Note: Small fits women sizes 0-2, medium fits women sizes 2-6, and large fits women sizes 6-12. Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash. Tank Top, $15.99 each Product Information: When the temperature rises, our 100% cotton Hanes Tank Top will help keep you cool. Preshrunk, durable and guaranteed. 5.5 oz. fabric made with 100% cotton open-end yarn Durable binding around the neck and armholes prevents stretching Double-needle bottom hem Preshrunk to minimize shrinkage Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash. Ladies Tank Top, $15.99 each Product Number: 2691569 In Stock: Will ship in 2-3 business days. Product Information: Always in style, our 100% cotton ladies tank top from Anvil will keep you cool when the temperature rises. Preshrunk, durable and guaranteed. Pre-shrunk heavyweight 5.6 oz. 100% cotton. Fashion cut for ladies. Bound-on rib around neck and armhole. Double needle bottom hem. Golf Shirt, $18.99 each The back is blank. Product Number: 2691576 In Stock: Will ship in 2-3 business days. Product Information: The perfect casual wear for the office, our Anvil golf shirts are made of 100% preshrunk, heavyweight cotton. Soft fashion knit collar and rib sleeve bands. Two woodtone buttons on a clean finished placket with 1/4" reinforced box. Double needle bottom hem. 5.6 oz preshrunk heavyweight cotton Knit collar Banded sleeves Two woodtone buttons Baseball Jersey, $18.99 each No image on the back Product Number: 2691591 In Stock: Will ship in 2-3 business days. Product Information: Our 100% Cotton Baseball Jerseys are popular with both men and women. Choose either Red or Black sleeves. 100% Preshrunk Cotton 5.9 oz Jersey (Tubular) ? Raglan Sleeves Double Needle Sleeves Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash. Long Sleeve T-Shirt, $20.99 each Product Number: 2691608 In Stock: Will ship in 2-3 business days. The most comfortable t-shirt ever! Our 100% cotton, Hanes Beefy-T is preshrunk, durable and guaranteed. 6.1 oz. fabric ? luxuriously soft 100% cotton ring-spun yarn Double-needle coverseamed neck Taped shoulder-to-shoulder Double needle sleeve and bottom hems Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash. Sweatshirt $22.99 each For the winter Product Number: 2691617 In Stock: Will ship in 2-3 business days. Product Information: Stay warm with our Hanes Heavyweight 50/50 cotton/polyester sweatshirts. Thick (but not bulky), comfortable, durable and guaranteed. 9 oz. patented PrintPro? fabric in a 50/50 cotton/polyester blend Double-needle coverseamed collars, armholes and waistband Densely knit fabric for a smooth printing and embroidery surface Spandex trim in the neck, cuffs and waistband Preshrunk to minimize shrinkage Our printing is better than ever ? full of detail and color ? and virtually fade resistant wash after wash.
×
×
  • Create New...